Actively Recruiting
Optimization of the Targeted Anticancer Therapies
Led by Centre Hospitalier Universitaire Vaudois · Updated on 2020-07-23
500
Participants Needed
1
Research Sites
813 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire Vaudois
Lead Sponsor
C
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study includes an observational pharmacokinetic study and an interventional medication adherence study. The purpose of this study is 1) to describe the concentration-time profiles of targeted anticancer drugs and to characterize the concentration-effect/toxicity relationships in the target population of patients (observational study) and 2) to characterize patterns of adherence to oral targeted anticancer drugs and identify key-driver modifiable adherence factors in patients participating in an adherence program (interventional study).
CONDITIONS
Official Title
Optimization of the Targeted Anticancer Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cancer patients to whom a targeted anticancer therapy is prescribed
You will not qualify if you...
- Patients incapable of judgment or participants under tutelage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHUV
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
Research Team
C
Chantal Csajka, PharmD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here